Kelnar K - Search Results

1

Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours.

Hong DS, Kang YK, Borad M, Sachdev J, Ejadi S, Lim HY, Brenner AJ, Park K, Lee JL, Kim TY, Shin S, Becerra CR, Falchook G, Stoudemire J, Martin D, Kelnar K, Peltier H, Bonato V, Bader AG, Smith S, Kim S, O'Neill V, Beg MS. Hong DS, et al. Among authors: kelnar k. Br J Cancer. 2020 May;122(11):1630-1637. doi: 10.1038/s41416-020-0802-1. Epub 2020 Apr 2. Br J Cancer. 2020. PMID: 32238921 Free PMC article. Clinical Trial.

2

In-depth analysis shows synergy between erlotinib and miR-34a.

Zhao J, Kelnar K, Bader AG. Zhao J, et al. Among authors: kelnar k. PLoS One. 2014 Feb 14;9(2):e89105. doi: 10.1371/journal.pone.0089105. eCollection 2014. PLoS One. 2014. PMID: 24551227 Free PMC article.

3

A qRT-PCR Method for Determining the Biodistribution Profile of a miR-34a Mimic.

Kelnar K, Bader AG. Kelnar K, et al. Methods Mol Biol. 2015;1317:125-33. doi: 10.1007/978-1-4939-2727-2_8. Methods Mol Biol. 2015. PMID: 26072405

4

Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34.

Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D, Bader AG. Wiggins JF, et al. Among authors: kelnar k. Cancer Res. 2010 Jul 15;70(14):5923-30. doi: 10.1158/0008-5472.CAN-10-0655. Epub 2010 Jun 22. Cancer Res. 2010. PMID: 20570894 Free PMC article.

5

Quantification of therapeutic miRNA mimics in whole blood from nonhuman primates.

Kelnar K, Peltier HJ, Leatherbury N, Stoudemire J, Bader AG. Kelnar K, et al. Anal Chem. 2014 Feb 4;86(3):1534-42. doi: 10.1021/ac403044t. Epub 2014 Jan 17. Anal Chem. 2014. PMID: 24397447 Free PMC article.

6

PDL1 Regulation by p53 via miR-34.

Cortez MA, Ivan C, Valdecanas D, Wang X, Peltier HJ, Ye Y, Araujo L, Carbone DP, Shilo K, Giri DK, Kelnar K, Martin D, Komaki R, Gomez DR, Krishnan S, Calin GA, Bader AG, Welsh JW. Cortez MA, et al. Among authors: kelnar k. J Natl Cancer Inst. 2015 Nov 17;108(1):djv303. doi: 10.1093/jnci/djv303. Print 2016 Jan. J Natl Cancer Inst. 2015. PMID: 26577528 Free PMC article.

7

Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancer.

Zhao J, Guerrero A, Kelnar K, Peltier HJ, Bader AG. Zhao J, et al. Among authors: kelnar k. Lung Cancer. 2017 Jun;108:96-102. doi: 10.1016/j.lungcan.2017.02.020. Epub 2017 Mar 1. Lung Cancer. 2017. PMID: 28625657

8

The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44.

Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, Wiggins JF, Bader AG, Fagin R, Brown D, Tang DG. Liu C, et al. Among authors: kelnar k. Nat Med. 2011 Feb;17(2):211-5. doi: 10.1038/nm.2284. Epub 2011 Jan 16. Nat Med. 2011. PMID: 21240262 Free PMC article.

9

A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer.

Kasinski AL, Kelnar K, Stahlhut C, Orellana E, Zhao J, Shimer E, Dysart S, Chen X, Bader AG, Slack FJ. Kasinski AL, et al. Among authors: kelnar k. Oncogene. 2015 Jul;34(27):3547-55. doi: 10.1038/onc.2014.282. Epub 2014 Sep 1. Oncogene. 2015. PMID: 25174400 Free PMC article.

10

Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes.

Takeshita F, Patrawala L, Osaki M, Takahashi RU, Yamamoto Y, Kosaka N, Kawamata M, Kelnar K, Bader AG, Brown D, Ochiya T. Takeshita F, et al. Among authors: kelnar k. Mol Ther. 2010 Jan;18(1):181-7. doi: 10.1038/mt.2009.207. Epub 2009 Sep 8. Mol Ther. 2010. PMID: 19738602 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

20 results

Search Page

Filters